DLRC Regulatory Consultancy’s Post

BioM Biotech Cluster Development GmbH’s highly anticipated event #BayOConnect - Forum for Biotech & LifeScience is coming up in Munich for the next two days! On July 2 the focus will be how to “Connect to Investment”, while on July 3, the spotlight will be on one of the biggest trends in Life Sciences exploring how to “Connect to AI”.   You won’t want to miss out on these program highlights featuring our clients:   “Risk and Reward - Comparative Strategies in Biotech Funding” June 2, 1:30 PM, with Olivier Litzka of Andera Partners   “Spotlight: Are we ready for AI?” June 3, 2:10 PM, with Dr. Friedrich von Bohlen of Molecular Health   Also, make sure to join the Pitch Session on June 2 at 2:30 PM, and connect with other like-minded, innovative start-ups such as AATec Medical and Mallia Therapeutics.   We can also recommend checking out the latest scientific posters during the breaks, including:    Secarna Pharmaceuticals: “Leading independent European antisense drug discovery & development company”  AATec Medical: “Novel Therapeutics for Globally Increasing Respiratory Diseases”   Schedule a meeting with our MC Services colleagues Eva Bauer, Dr. Cora Kaiser, Regina Lutz and Philipp Streng to find out more about how we support Life Science companies with expert Corporate Communications and Investor Relations insights: https://lnkd.in/d6ikVBPw   You can find the full agenda and the latest news from BayOConnect here: https://lnkd.in/dGMqmzYS #BayOConnect #LifeSciences #CorporateCommunications #InvestorRelations #MCServices #Networking #Biotech #Startup #Bayern #BioM 

🌍 Exciting News! iBio, Inc.'s Chief Financial Officer, Felipe D., will be attending #BioEurope2024 in Stockholm, Sweden, next month! 🌍 This key event brings together top biotech and pharma leaders and over 5,000 industry professionals. Felipe will discuss iBio’s innovative AI-driven platform and explore potential partnerships for our growing pipeline in immuno-oncology and cardiometabolic diseases. At iBio, we're leveraging machine learning and epitope engineering to accelerate drug discovery and development—making major strides in tackling some of the most challenging targets. 💡 Interested in connecting with Felipe? Drop a message or schedule a meeting at the event! Let’s explore how we can collaborate. #BioEurope #Biotech #AI #ImmunoOncology #Cardiometabolic #MachineLearning #Partnerships #DrugDiscovery #Pharma #iBio

[#BIO2024] France 2030 Snapshot: Not 1, not 2... but 26 laureates from the France 2030 investment plan in 2024 are part of the French delegation! 🪙 The France 2030 investment plan, implemented by the French Government, supports innovative actors throughout France. Its aim is to accelerate the transformation of key sectors of the economy through innovation and to position France as a leader in the world of tomorrow, including in the Healthcare ecosystem. 🌱 These companies are at the forefront of innovation, showcasing groundbreaking solutions that promise to shape the future of the industry. 🤝 Their participation offers valuable insights, expertise, and potential partnerships to forge meaningful connections with American counterparts. Our warmest congratulations to these remarkable companies: Brenus Pharma - ABCELY - SynapCell - Iktos - NG BIOTECH - Stromacare SAS - Averoa - Owkin - Persea - NETRIS Pharma - Altevax Biotech - Fabentech - Affilogic - WhiteLab Genomics - Lys Therapeutics - XENOTHERA - SATT AxLR - ETAP-Lab - Preclinical CRO - Phost'in Therapeutics - Institut Pasteur - Apmonia Therapeutics - SurgeCare - OSE Immunotherapeutics - MaaT Pharma - BioValley France - Aurora Sterilisation - BIOASTER Learn more about the Healthcare innovation France 2030 plan: https://lnkd.in/eJ8YzZe2 French Healthcare - #innovation #biotech

🌟 Exciting Collaboration Alert! 🌟 Integrated Biosciences, Inc. and Illumina Ventures Labs are teaming up to revolutionize the world of novel therapeutics by targeting the transcriptome! 🧬✨ This innovative partnership aims to leverage cutting-edge technologies to develop groundbreaking treatments and advance healthcare. 🌐 By focusing on the transcriptome, they are opening new doors in precision medicine and bringing us closer to personalised therapies. This collaboration signifies a major step forward in the biotech industry, promising innovative solutions for complex diseases. 🔬 Stay tuned for more updates as these two powerhouses drive forward the future of therapeutic development! #Biotech #HealthcareInnovation #PrecisionMedicine #Transcriptome #NovelTherapeutics #IntegratedBiosciences #IlluminaVentures #LifeSciences #MedicalBreakthroughs 🚀💡

#DrugDiscovery Bina - Bridge Innovate Nurture Advance Launched a New Track for Drug Discovery. We announce the launch of a new track for drug discovery at Bina. This initiative aims to bring together Weizmann Institute of Science scientists and world-class experts from the #pharmaceutical and #drug development industries, as well as #clinical practice. Harnessing Weizmann’s deep and innovative basic science research into the discovery of #disease #mechanisms and #molecular and #cellular pathways can lead to the development of new targets and #therapeutic agents. We would like to thank our SAB committee for their significant contribution: Isaac Kohlberg from Harvard University, Aya Jakobovits; Opher Shapira, CEO of YEDA - Technology Transfer Company of Weizmann Institute of Science and Irit Sagi, VP Innovation and Technolgy Transfer at the Weizmann Institute. #Innovation #DrugDiscovery #BiomedicalResearch #TranslationalScience #WeizmannInstitute #Bina Sharon Fireman, Merav Marom, Hezi Sztainberg, Ph.D., Opher Shapira, Elik Chapnik, Yael Klionsky, Reut Magor, Orel Yaverbaum, Irit Sagi

September 30 - October 1! Fierce Biotech Summit in the Seaport. ‘This two-day summit brings together the brightest minds in biotech to exchange groundbreaking ideas and real-world applications. Attendees will have the chance to delve into critical discussions on the latest industry trends, including the biotech IPO outlook, developments in cell therapy and the transition from corporate communications to corporate affairs. Experts in the industry will also dive deep into how the industry has navigated regulatory challenges and market changes through strategic deals and innovative approaches.’ #biotech #biotechnology #biotechnologie #networking #likeandshare

A 12-year-old Swiss biotech seeks to make its mark in the space of anti-tau Alzheimer's medicines, and it's moving ahead in the same niche as the field's two biggest drugmakers: Eli Lilly and Biogen. With a $100 million Series C, Asceneuron hopes to prove that an O-GlcNAcase (OGA) inhibitor can help thwart or slow down cognitive declines and do so with an oral treatment, rather than complex and healthcare-straining infusions. “Lilly will hopefully validate this class later on this year, and then we are second after that in a very large market,” Naveed Siddiqi said in an interview with Endpoints News. The Novo Holdings venture investments senior partner said it’s believed that tau is “more highly correlated with the loss of your cognition than amyloid is.” More from my interview with Asceneuron SA's CEO Barbara A. and Ryan S.: #alzheimers #tau #dementia #alzheimersresearch #drugdevelopment #ogainhibitor #biotech #venturecapital

🚀 "Organ-on-chips (OoC) Innovations Unveiled: Industry Collaborations" 📢 Post #4: We are exploring various aspects of industrial-OoC makers collaborations as a part of a series 'OoC Innovations Unveiled: Industry Collaborations'. Extensive Validation: A Key to Successful OoC Startups: 🌟 The path to triumph in the OoC field passes through extensive validation phase. Industry partnerships offer the perfect validation ground, ensuring that OoC models are robust and market-ready. 🔍 Today's focus: In this last post, we have compiled the list of publications with DOI under each organ model. Moreover, this report also contains the plotted data from the last three posts. 📊 From 70 collaborative studies top two broader areas are: (1) ADME&T: 39 studies (2) Disease modeling: 21 studies >It is expected that OoC will be greatly useful for the development of biologics. We found 3 of such studies that involved biologics. >Majority of the cancer-on-chips models investigated efficacy of immunotherapies. 🔗 Source: listed publications on the websites of OoC makers. 📝 Note: This dataset encompasses studies published up to 2023. Therefore, it does not include any unpublished or ongoing studies that are part of strategic partnerships. Additionally, this post does not aim to promote or demote any OoC company. #organonchip #collaboration #innovation #drugdiscovery #3dcellculture #biotechinnovation #industrycollaboration #venturecapital

I could not help but share insights from a recent video highlighting an OSHA reportable rate of 0.06% within a company, showcasing exemplary planning and project management. Their innovative facility replication strategy promises to reduce carbon footprints and refine processes. Exciting discussions emerged about replicating successful features from their North Carolina facility at their Denmark site. #ProjectManagement #Innovation #SafetyStandards

So Many Conferences — So Little Time: Which Conference to Visit? I often get asked by companies and industry stakeholders which conferences they should visit or which are worth attending in the first half of the year. I have been in the circle for 25 years now and there is no straight answer. The standard response is, it depends on what you are looking for. If you are looking for general partnering, there are a number of big conferences like the "BIO International Convention" and "#bioeuropespring ", where you can meet people from all over the world. However, there are also some (smaller) regional-focused conferences like the "Swiss Biotech Day #swissbiotechday", which has grown to over 1,800 participants, or the "Asia Bio Partnering Forum #ASIABIO" and "BIO KOREA". There are also therapeutic or technology-focused conferences like "Advanced Therapies" in London, "Festival of Biologics" in San Diego, or "The World Vaccine Congress" in DC. If you are fundraising, there are options like the "BIO CEO & Investor Conference" in NY for more mature (public) companies, "RESI Conferences Life Science Nation (LSN)" (Atlanta and Barcelona) for earlier stage (private) companies, as well as "LSX World Congress" in London or "The Annual European Life Sciences CEO Forum #Sachs_ELSF" in Zurich. Additionally, different investment banks host conferences, of which "JPM JPMorgan Chase & Co." in San Francisco is where the industry meets. For very intimate interactions with other Biotech CEOs, I can recommend the "Biotech CEO Summit CEO Summit by Demy-Colton" in Barcelona and La Jolla. You can find all these conferences, along with their dates and links here » https://lnkd.in/dawnkF6p